Novo Nordisk and Eli Lilly Report GLP-1 Drugs May Slow Biological Aging
Novo Nordisk, Eli Lilly Report GLP-1 Signals of Slowed Biological Aging at ARDD
At the ARDD conference, Novo Nordisk and Eli Lilly presented early signals that GLP-1 drugs — the class behind Ozempic and similar treatments — may slow biological aging, not just drive weight loss. Hacker News commenters reacted with a mix of enthusiasm and skepticism, debating unknown side effects and pointing to litigation over alleged blindness risks, while others noted that millions of patients already take these drugs without any mass harm appearing.
Many here have expressed skepticism at GLP1s because they don't require the personal discipline of caloric deficit and might have unknown side effects. So far, all the unknown side effects I've read about have been like this.